TrialCancer chemotherapy and pharmacology2026

Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study.

Robert Bell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.